Cybin D/B/A Helus Pharma HELP
Set alert
9.29 USD +0.49 +5.57%
As of Nov 3, 11:06 AM ET
8.94 Day range 9.57
3.76 52-week range 15.15
- YTD
- +13.57%
- 1 year
- +38.04%
- Open
- 9.00
- Prev close
- 8.80
- Mkt cap
- 678.82M
- Vol
- 525.42K
- Avg vol
- 1.75M
- EPS
- -4.15
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.94
- High
- 9.57
- Forward P/E
- -7.55
- Beta
- 0.63
- Short ratio
- 1.59
- Inst. own
- 41.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 10.70
- 200-d avg
- 7.11
- 1y target
- 40.24
5D chart
Signals (117)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 2:00 PM | 21 hours ago |
| MACD: Buy Signal | Nov 2, 2:00 PM | 21 hours ago |
| MACD: Sell Signal | Nov 2, 1:15 PM | 21 hours ago |
| RSI: Oversold | Nov 2, 1:00 PM | 22 hours ago |
| SMA: Bearish | Nov 2, 12:05 PM | 23 hours ago |
| MACD: Buy Signal | Nov 2, 11:30 AM | 23 hours ago |
| SMA: Bullish | Nov 2, 11:25 AM | 23 hours ago |
| RSI: Oversold | Nov 2, 10:25 AM | 1 day ago |
| RSI: Oversold | Nov 2, 10:05 AM | 1 day ago |
| RSI: Oversold | Nov 2, 9:40 AM | 1 day ago |
| SMA: Bearish | Nov 2, 9:35 AM | 1 day ago |
| SMA: Bearish | Nov 2, 9:35 AM | 1 day ago |
| MACD: Sell Signal | Nov 2, 9:35 AM | 1 day ago |
| SMA: Bullish | Nov 2, 9:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 3:35 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:30 PM | 3 days ago |
Newest 20 of 117.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 40.24 +333.2% upside
Now 9.29
- Target (low)
- 15.08
- Target (mean)
- 40.24
- Target (high)
- 69.16
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy1
- Buy10
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 10
- 2 months ago 10
- 3 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.9448 | -1.15 – -0.569 | -1.65 | +42.9% | 0 | 0.0% | 5 |
| Next quarter | -0.8782 | -1.07 – -0.638 | -1.36 | +35.6% | 0 | 0.0% | 5 |
| Current year | -3.71 | -4.43 – -2.86 | -5.91 | +37.4% | 0 | 0.0% | 4 |
| Next year | -2.54 | -3.04 – -2.04 | -3.71 | +31.4% | 11.07M | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2026 | Barclays | Initiated | — | Overweight |
| Aug 20, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jul 27, 2026 | Wells Fargo | Initiated | — | Overweight |
| Jul 9, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 1, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Apr 13, 2026 | TD Cowen | Initiated | — | Buy |
| Mar 2, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 3, 2025 | Guggenheim | Maintained | Buy | Buy |
| Nov 20, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 14, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |